Pulmatrix

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2003-01-01

Employees: 22

Market Cap: $7.5M

Website: http://www.pulmatrix.com

Clinical Trials

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Phase 2

Terminated

Conditions: ABPA

Interventions: Drug: Placebo
Drug: Itraconazole Powder

First Posted Date: 2022-12-28

Last Posted Date: 2024-04-02

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 8

Registration Number: NCT05667662

Locations: 🇺🇸
Southern Illinois University Center for Clinical Research, Springfield, Illinois, United States
🇺🇸
Bensch Clinical Research, Stockton, California, United States
🇬🇧
University Hospitals Birmingham - Heartlands Hospital, Birmingham, West Midlands, United Kingdom

and more 15 locations

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dihydroergotamine (D.H.E 45)
Drug: PUR3100
Other: Matching Placebo for D.H.E 45
Other: Matching Placebo for PUR3100

First Posted Date: 2022-04-28

Last Posted Date: 2022-12-23

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 26

Registration Number: NCT05351086

Locations: 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia

A Phase 1b Study of PUR1800 in Patients With COPD

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo Comparator
Drug: PUR1800 250 ug
Drug: PUR1800 500 ug

First Posted Date: 2021-02-18

Last Posted Date: 2022-06-27

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 18

Registration Number: NCT04759807

Locations: 🇬🇧
Medicines Evaluation Unit Ltd., Manchester, Wythenshawe, United Kingdom

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Phase 2

Terminated

Conditions: Allergic Bronchopulmonary Aspergillosis

Interventions: Combination Product: PUR1900
Combination Product: Placebo

First Posted Date: 2019-05-23

Last Posted Date: 2021-08-27

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 7

Registration Number: NCT03960606

Locations: 🇵🇱
Uniwersyteckie Centrum Kliniczne - PPDS, Gdansk, Pomorskie, Poland
🇮🇳
Yashoda Hospital, Hyderabad, Andhra Pradesh, India
🇵🇱
PULMAG Arkadiusz Brodowski, Grzegorz Gasior S. C., Sosnowiec, Slaskie, Poland

and more 17 locations

Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Itraconazole Powder
Drug: Itraconazole 200 mg

First Posted Date: 2018-03-27

Last Posted Date: 2018-07-27

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 58

Registration Number: NCT03479411

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom

A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PUR0200
Drug: Reference Product

First Posted Date: 2016-02-02

Last Posted Date: 2016-11-11

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 42

Registration Number: NCT02671825

Locations: 🇧🇬
Tokuda Hospital, Sofia, Bulgaria

A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

Phase 1

Terminated

Conditions: Postoperative Wound Infection-deep
Post Operative Wound Infection

Interventions: Drug: RUT058-60
Drug: Sterile saline for irrigation

First Posted Date: 2014-10-31

Last Posted Date: 2021-01-12

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 9

Registration Number: NCT02280395

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸
BJJS, Corp., Memorial Hermann Memorial Medical Center, Houston, Texas, United States

and more 1 locations

21 Day Cumulative Skin Irritation of RUT058-60

Phase 1

Completed

Conditions: Irritation/Irritant

Interventions: Drug: 0.9% Physiological Saline, USP
Drug: Hypochlorous acid solution 106 mg/L
Drug: 0.1% (w/v) Sodium Lauryl Sulfate

First Posted Date: 2014-07-24

Last Posted Date: 2016-02-04

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 43

Registration Number: NCT02198963

Locations: 🇺🇸
BioScience Laboratories, Inc., Butte, Montana, United States

A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: PUR0200
Drug: PUR0200 Placebo
Drug: Active comparator

First Posted Date: 2013-08-13

Last Posted Date: 2014-03-18

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 38

Registration Number: NCT01921712

Locations: 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧
Quotient Clinical, Nottingham, United Kingdom

Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: PUR118

First Posted Date: 2012-09-24

Last Posted Date: 2013-07-19

Lead Sponsor: Pulmatrix Inc.

Target Recruit Count: 24

Registration Number: NCT01690949

Locations: 🇩🇪
Fraunhofer Institut fur Toxicologie und Experimentelle Medicine (ITEM), Hannover, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy